The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
Coccidiodes immitis , 7 , 19
dengue virus, 345–346
diabetes, 387
Epstein-Barr virus, 329 , 333
funding, 125
gonorrhea, 371
herpes simplex virus, 327
mycobacterium tuberculosis, 352 , 353–354 , 355
papillomaviruses, 342
programmed T-cell death, 397–398
respiratory syncytial virus, 6 , 19
streptococcus, group A, 362 , 363
Cloning, 26 , 36
Coccidiodes immitis , 7 , 19 , 44 , 54 , 88 , 90 , 91 , 159–164 , 356–359
Cognitive impairments, 62 , 64–65
Combination vaccines, 9 , 18 , 38 , 46–47 , 75 , 130 , 436
elicobacter pylori , 364 , 366–367
herpes simplex virus, 327
Computer technology
committee’s model, application of, 13 , 95
Internet, IOM, 4 , 323
physician reminders, 48
Confidentiality, 47
Conjugate vaccines
Haemophilus influenzae , 11
varicella-zoster virus, 11 , 18
Cost and cost-effectiveness analysis, general, 2–3 , 11 , 12 , 17 , 20 , 435–436 , 437
age factors, analytic approach of model, 60 , 66 , 68–69 , 80–83 , 84
age factors, detailed review of model, 93 , 95 , 98–100 , 101–103 , 105
aggregation, 2 , 56 , 117–118 , 119
children, 46
combination vaccines, 47
death rates, analytic approach of model, 61–62 , 66 , 68 , 78–79 , 80–83 , 86
death rates, detailed characterization of model, 95 , 97–98 , 100 , 103–104
defined, 56
discounting, 18 , 60–61 , 68–69 , 74 , 80 , 83 , 85–86 , 97–98 , 99 , 101–103 , 105–107 , 114–115
ethical issues, 3–4 , 58 , 75 , 109–122 , 128 , 129
licensure possibilities, scope of study at hand, 39 , 40 , 43
licensure process, 19–20 , 54–55 , 58 ;
see also Time factors
life expectancy, analytic approach of model, 57 , 66 , 68 , 76 , 120
life expectancy, detailed characterization of model, 95–96 , 98 , 99 , 101–102 , 103 , 104 , 106–107
mathematical formulae, 94–97 , 99 , 101–106 (passim)
model, analytical approach, 53–92
model, detailed description, 93–108
morbidity/morbidity scenarios, analytic approach of model, 61–66 , 67 , 68 , 69 , 71 , 76 , 78–79 , 80–85
morbidity/morbidity scenarios, detailed characterization of model, 95 , 96 , 97 , 98 , 108
opportunity costs, 74 , 115–116 , 130
polio, 25–26
pregnant women, 22
ranking of vaccines covered, 5–8
reasons for, 57
sensitivity analysis, 3 , 57
specific diseases/pathogens/vaccines,
lists of, 54–55 , 87–91
review for each, 143–433 ;
see also diseases/pathogens/vaccines found in lists
utilization of vaccines, analytic approach of model, 72–73 , 75 , 76 , 79 , 80 , 86 , 88 , 89 , 91
utilization of vaccines, detailed characterization of model, 95 , 107–108
see also Death rates; Efficacy of vaccines; Morbidity scenarios; Quality-adjusted life years
Contraceptive vaccines, 75–76
Costimulation, 372 , 373 , 375 , 389 , 398 , 399 , 400 , 401 , 402 , 407–412 , 419
